7 results
424B5
MDGL
Madrigal Pharmaceuticals, Inc.
20 Mar 24
Prospectus supplement for primary offering
4:06pm
and the demographics of patients eligible for Rezdiffra, which may be different than what we currently expect;
the occurrence of any side effects
424B5
MDGL
Madrigal Pharmaceuticals, Inc.
18 Mar 24
Prospectus supplement for primary offering
4:08pm
and the demographics of patients eligible for Rezdiffra, which may be different than what we currently expect;
the occurrence of any side effects, adverse reactions
8-K
EX-99.1
xiw418 cf1eytd
3 Jun 13
Synta Announces Positive Overall Survival Results From GALAXY-1 Phase 2b/3 Trial of Ganetespib in Second-Line Non-Small Cell Lung Cancer
12:00am
- Prev
- 1
- Next